ENJA

Every Life Deserves A Bright Future

News

Mission

To create the society without people left behind

In an aging society with a declining birthrate, it is important not only to extend healthy life expectancy, but also to maintain the number of healthy children. We try to solve the problems of both pediatric and aging diseases.

About FELIQS

Developing novel medicines
targeting ferroptosis / oxidized lipid

FELIQS【fíːlɪks】 is a preclinical-stage start-up company established based on the robust science from molecular pathobiology, department of pharmaceutical science, Kyushu university.

Ferroptosis is a new type of cell death reported in 2012(Cell. 2012 May 25;149(5):1060-72.), and it is caused by the accumulation of oxidized lipids. In recent years, it has been reported to be associated with many diseases such as cancer, ischemia-reperfusion injury, and neurodegenerative diseases, and is being investigated as a new drug target. We have established a unique drug discovery platform targeting ferrotosis/oxidized lipids, and are now conducting preclinical research toward the clinical trial to create new medicine for unmet medical needs in ophthalmology space.

Name

FELIQS CORPORATION

Address
1-1 Hyakunenkoen, Kurume, Fukuoka, 8390864, JAPAN
US Office
JLABS@NYC 101 6th Ave 3rd floor, New York, NY 10013, U.S.A
Capital
50,500,000 JPY
Main bank
MUFG bank
Investors
Mitsubishi UFJ Capital, Keio Innovation Initiative, FFG Venture Business Partners, Kurume Research Park

Business

Pipeline

Code Target
Indications
administration
Route
Regulatory
Pathway
Preclinical Clinical
Discovery / Research Lead optimization IND enabling Phase I/II
FLQ-101 Retinopathy of Prematurity (ROP) Intravenous 505(b)(2)
FLQ-104 Geographic Atrophy / wet AMD Oral 505(b)(1)

Member

Ken-ichiro Kuninobu
Ken-ichiro Kuninobu,
Ph.D., RPh
Co-founder and CEO
Dr.Kuninobu has 15 years+ experience in the pharmaceutical industry. He led the US regulatory and clinical affairs of the department of regenerative medicines in NIPRO until 2022 in collaboration with Yale University
Ken-ichi Yamada
Ken-ichi Yamada,
Ph.D.
Co-founder and CSO
Professor of Kyushu University. Dr.Yamada is the Principal investigator of basic research on elucidation of disease mechanisms and drug discovery by targeting oxidized lipids. He worked as a research fellow in NIH(NIH/NCI: Dr. Murali C. Krishna)
MaryJane Rafii
MaryJane Rafii, Ph.D, MBA
Director, Business Development & Finance
With 20 years+ of biotech and pharmaceutical industry experience, MaryJane brings expertise on Buy and sell-side, Mergers and Acquisitions, Equity Investment, Business Development, licensing, and Corporate Strategy, at Multinational Pharma companies and US private and global small midcaps with value-creating transformative transactions.
Samir Tari
Samir Tari,
M.D., MBA
Consultant Medical Director
Dr.Tari has 16 years+ experience as a pharmaceutical executive in ophthalmology. He served as Senior Director of Medical Affairs at Regeneron, Global Medical Lead, and Senior Medical Director at Astellas.
Robert Armenti
Robert Armenti, MSc
Consulting Clinical Trial Manager
Mr. Armenti has 30 years+ experience in pharmaceutical clinical development and operations supporting daily execution of studies during all stages of clinical trials. He worked in the Molecular Biology Department and transitioned to Clinical Development while at Ciba-Geigy and continued to expand his capability in Daiichi Sankyo and other pharmaceutical companies.
Christian Ofslager
Christian Ofslager
CMC Expert
Christian Ofslager has spent 35 years in sterile drug development and manufacturing and has developed several commercial products and has wide experience in developing liquid & lyophilized vial, frozen bag and prefilled syringe drug products. During that time he spent 24 years in Wyeth formulations development and 10 years at Pfizer in development and manufacturing.
Aiko Kato Sullenberger
Aiko Kato Sullenberger
Boston Operations Manager
Aiko has ten years of experience in research and business development in Daikin Global HQ. She handles its CVC operation in Boston up to 2020. In Allm USA, she engaged in scouting opportunities to digital health solutions to US medical institutions. Experience at CIC expanded her network of life science and VCs in greater Boston area.

Advisors

Robert M. Ward
Robert M. Ward, M.D.
Professor Emeritus
Dr.Ward was the former chair of the American Academy of Pediatrics Committee on Drugs began the Pediatric Pharmacology Program at the University of Utah School of Medicine and served as an attending neonatologist and medical director of the Primary Children’s Hospital NICU. He has published widely and lectured internationally.
Darius M. Moshfeghi
Darius M. Moshfeghi, M.D.
Chief of Retina Professor of Ophthalmology Stanford University School of Medicine
Dr.Moshfeghi is an internationally-recognized expert in pediatric vitreoretinal disease and pediatric retinal telemedicine. He has dedicated his career to using telemedicine and digital technology to prevent blindness in children.
Kelly C. Wade
Kelly C. Wade, M.D., Ph.D.
Professor of Clinical Pediatrics, University of Pennsylvania
Dr. Wade is an attending neonatologist at CHOP Newborn Care at Pennsylvania Hospital and CHOP, as well as professor of Clinical Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Her research focuses on clinical care of infants in the NICU.
Kenichi Shimada
Kenichi Shimada, Ph.D.
Research Associate
Laboratory of Systems Pharmacology Harvard Medical School
Dr.Shimada received his Ph.D. for the elucidation of the mechanisms of ferroptosis, a form of non-apoptotic cell death phenotype, under the supervision of Dr. Brent Stockwell at Columbia Univeristy. In 2015, he came to HMS and continued his training as a postdoctoral fellow with Dr. Timothy Mitchison and has published a few papers in mechanistic toxicology and cancer signaling.
Norman Barton
Norman Barton, M.D., Ph.D.
Ex-Global Head Clinical Sciences Rare Metabolic Disorders and Neonatology in Takeda(Shire)
Dr.Barton is an experienced executive with substantive accomplishments in rare diseases. He has 40 years of experience in orphan drug product development in leadership positions with strategic, operational, and management responsibilities at Takeda and Shire, including the retinopathy of prematurity (ROP) program.
Robert Bhisitkul
Robert Bhisitkul, M.D., Ph.D.
Professor of Retina of UCSF.
Dr.Bhisitkul is an ophthalmologist and retina specialist who provides medical and laser treatment for macular degeneration, diabetic retinopathy and other retinal diseases. He also performs surgery on macular hole and macular pucker, retinal detachment and complications of diabetic eye disease.

Contact

Feel free to write down your inquiry in the following form.

Please enter here to input your inquiries

PAGE TOP